Navigation Links
BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study
Date:7/25/2011

RALEIGH, N.C., July 25, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today that the last patient has completed the randomized portion of its Phase 3 clinical trial assessing the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain, signifying completion of the trial.

(Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO)

"We are very pleased to have brought to completion our Phase 3 efficacy study for BEMA Buprenorphine in the management of chronic pain," stated Dr. Andrew Finn, Executive Vice President of Product Development at BDSI.  "We have achieved our aggressive recruitment and enrollment goals and anticipate reporting top line results in mid to late September of this year.  Over the next several weeks, we will be completing the administrative activities that will lead to a database lock followed by statistical analysis and the availability of top line results.  Assuming positive study results, we would hope to be in a position to file a New Drug Application (NDA) for this product in the first half of 2012."

BDSI believes that there remains a significant unmet medical need for potent new analgesics for the treatment of chronic pain.  The company believes that buprenorphine is an attractive option for development because of its potent analgesic properties, its differentiating characteristics from other opioids and its DEA Schedule III designation, which means there is less addiction potential than Schedule II products such as oxycodone and morphine.  In addition, BDSI believes that BEMA Buprenorphine has the potential to be the first oral transmucosal form of buprenorphine to treat chronic pain in the U.S.  According to Wolters Kluwer, opioid analgesic sales in the U.S. are in excess of $10 billion and growing, and BDSI believes that BE
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sangamo BioSciences Announces Efficient Generation of Transgenic Pigs Using Zinc Finger Nuclease (ZFN) Technology
2. Sangamo BioSciences Announces Second Quarter 2011 Conference Call and Webcast
3. Cell Biosciences Changes Name to ProteinSimple
4. Sofie Biosciences is Awarded a DOE Phase I SBIR to Commercialize Microscale Radiochemistry Platform
5. SANYO and BD Biosciences Collaborate to Offer Researchers Valuable Technology and Research Tools
6. Leading Life Sciences Luminaries Connect at Innovation Ireland Reception
7. Scotland Announces Goal to Double Life Sciences Contribution to Scottish Economy by 2020 at BIO
8. Neurocrine Biosciences Announces Notice of Allowance for Composition of Matter Patent on VMAT2 Inhibitor
9. Indianas $44 Billion Life Sciences Industry Packs a Powerful Punch
10. Proceedings of the National Academy of Sciences (PNAS) Publishes Roche Manuscript on Production of Bispecific IgG Antibodies
11. New Jersey Targets Life-Sciences Investors at Worlds Largest Biotechnology Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... (PRWEB) April 28, 2015 The ... a Massachusetts-based multi-stakeholder, non-profit organization dedicated to transforming ... a shared global system for clinical research, announced ... an innovative new type of clinical research event ... of clinical research is changing,” said Greg Koski, ...
(Date:4/27/2015)... , Alemania, April 27, 2015 ... nuevo receptor utilizando tecnología de descubrimiento de biomarcador computacional  ... el tratamiento de millones de pacientes con cáncer   ... ha recibido una patente en Europa titulada "Tissue Protective ... Molecular Health de que EPHB4 es un nuevo receptor ...
(Date:4/27/2015)... Deadly viruses such as Ebola are ... the University City Science Center's Port business ... With a $4.5 million Phase 2 SBIR grant from ... Therapeutics is focused on therapies for unmet medical ... is developing first-in-class protease inhibitors based on a technology ...
(Date:4/27/2015)... , April 27, 2015   Aratana ... pet therapeutics company focused on the licensing, development ... animals, today provided commentary on clinical study data ... a poster session at the American Association for ... ADXS31-164 is a novel Lm -LLO immunotherapy ...
Breaking Biology Technology:ACRES Announces Innovative Clinical Research Event--SYNERGY 2ACRES Announces Innovative Clinical Research Event--SYNERGY 3ACRES Announces Innovative Clinical Research Event--SYNERGY 4Molecular Health obtiene la patente para un nuevo receptor 2Molecular Health obtiene la patente para un nuevo receptor 3New Resident of Science Center’s Port Business Incubator Targets SARS and Ebola 2Aratana Therapeutics Comments on ADXS31-164 (AT-014) Study Data Presented During Poster Session at the American Association for Cancer Research (AACR) Annual Meeting 2015 2
... COLUMBIA, Md., Sept. 2 ACell, Inc. is announcing ... , , The conference will be held ... Palace Hotel in New York City. James DeFrancesco, Chief Executive Officer ... 11th beginning at 9:10 AM (EDT) in the Hubbard Room. The ...
... HAYWARD, Calif., Sept. 2 Advanced Cell Diagnostics, Inc. ... of its Series A equity financing from Morningside Ventures, bringing ... , , ACD will use the funds ... on the company,s patent pending RNAscope(TM) technology. "This second closing ...
... , , INDIANAPOLIS, Sept. 2 ... announced that, effective October 1, 2009, it would increase the ... kg for all non-contract customers or as existing contracts permit. ... invest in expanding global supply for the high performance, reducing ...
Cached Biology Technology:ACell's CEO to Present at Rodman & Renshaw's 2009 Annual Global Investment Conference 2ACD Completes the Second Closing of Series A Financing and Initiates Services for Biomarker Validation and Companion Diagnostic Development 2
(Date:4/20/2015)... PASADENA, Calif. , April 20, 2015 ... San Gabriel Valley to implant a new miniaturized, wireless ... HF System is the first and only FDA-approved heart ... reduce hospital admissions when used by physicians to manage ... a sensor that is implanted in the pulmonary artery ...
(Date:4/17/2015)... , April 17, 2015 ... concerns, and technological advancement to drive biometric systems ... until 2020   According to a ... Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems market in ... to register growth at CAGR of over 22% ...
(Date:4/14/2015)... 14, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces that ... 2015 New York Design Awards under the category  ,Product ... City Design Awards are part of a global multi-disciplinary ... ratings from the marketplace, industry and judging panel. Winners ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... 6, 2013) -- Researchers at Weill Cornell Medical College have ... circuits in a developing brain -- gaining unprecedented insight into ... from autism to mental retardation. In the journal ... faulty wiring occurs when RNA molecules embedded in a growing ...
... of treatment for patients with end-stage liver disease, the 12th ... research from the Icahn School of Medicine at Mount Sinai, ... today, suggests that it may one day become possible to ... disease. Investigators discovered that a human embryonic stem cell can ...
... of vitamin D are associated with high levels of hepatitis ... , a journal of the American Association for the Study ... HBV levels point to a link in these variables among ... are available, HBV still remains one of the most significant ...
Cached Biology News:Researchers discover how brain circuits can become miswired during development 2Researchers discover how brain circuits can become miswired during development 3Mount Sinai discovers new liver cell for cellular therapy to aid in liver regeneration 2Vitamin D deficiency may help spread of hepatitis B throughout liver 2
... mir Vana miRNA Bioarray Essentials Kit provides ... and post-hybridization washing of the mir Vana ... has been labeled using Ambions mir Vana ... positive control miRNA (Bioarray ID BA10001) that should ...
... Intracellular Localization Kit provides a straight forward ... of your design, in an efficient yet ... Subcellular localization and functional inhibition of target ... of the labeled siRNA into mammalian cells. ...
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: box ...
... The InnoCyte Laminin-Based 96-well Cell Invasion Assay ... of cells using laminin as a significant ... anti-metastatic agents in vitro in a convenient, ... size is appropriate for all types of ...
Biology Products: